Observational studyPloS one2023
Prevalence and knowledge about acute mountain sickness in the Western Alps.
Observational study in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06446427 (The Effect of Acute High Altitude Exposure on Rescuer Performance and Patient Care), which is not on this map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Acute High Altitude Exposure on Rescuer Performance and Patient Care
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Mountain sickness in altitude inhabitants of Latin America: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Effect of electro-thumbtack needles on symptoms during high-altitude exposure: a pilot, single-blind, randomized, controlled study.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Trial
- Genome-wide association study reveals acute mountain sickness susceptibility in Chinese population.Molecular genetics and genomics : MGG · 2026Article
- Qi deficiency constitution increases risk of acute mountain sickness via reduced aerobic fitness.Frontiers in public health · 2026Article
- High Altitude Pulmonary Edema Associated with Climbing Mount Fuji.Internal medicine (Tokyo, Japan) · 2025Article
- Changes and monitoring technology of human heart rate and blood oxygen saturation under high-altitude hypoxia.Frontiers in physiology · 2025Review
- Intelligent monitoring and individualized strategies for preventing altitude sickness during altitude training.Frontiers in physiology · 2025Review
- [Body Function Changes and Prevention Strategies in High-Altitude Environment].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Review
- Safety and efficacy of electro-thumbtack needle for acute mountain sickness patients: a protocol of a randomized, single-blinded, and placebo-controlled study.BMC complementary medicine and therapies · 2024Article
- Altitude illnesses.Nature reviews. Disease primers · 2024Review
- Incidence and risk factors of severe acute high-altitude illness in healthy adults first entering the northern Tibetan Plateau of over 5,000 m.Frontiers in public health · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the prevalence of acute mountain sickness (AMS) in 1370 mountaineers at four different altitudes in the Western Alps. We also examined the influence of potential risk factors and the knowledge about AMS on its prevalence.
methodsIn this observational cross-sectional study AMS was assessed on the day of ascent by the Lake Louise score (LLS, cut-off ≥3, version 2018) and the AMS-Cerebral (AMS-C) score of the environmental symptom questionnaire (cut-off ≥0,70). The latter was also obtained in the next morning. Knowledge regarding AMS and high-altitude cerebral edema (HACE) and the potential risk factors for AMS were evaluated by questionnaires.
resultsOn the day of ascent, the prevalence of AMS assessed by the LLS and AMS-C score was 5.8 and 3.9% at 2850 m, 2.1 and 3.1% at 3050 m, 14.8 and 10.1% at 3650 m, and 21.9 and 15% at 4559 m, respectively. The AMS prevalence increased overnight from 10.1 to 14.5% and from 15 to 25.2% at 3650 m and 4559 m, respectively, and was unchanged at 2850 m and 3050 m. A history of AMS, higher altitude, lower degree of pre-acclimatization, and younger age were identified as risk factors for developing AMS. Slow ascent was weakly associated with AMS prevalence, and sex and knowledge about AMS and HACE were indistinct.
conclusionAMS is common at altitudes ≥ 3650 m and better knowledge about AMS and HACE was not associated with less AMS in mountaineers with on average little knowledge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.